Michael Klichinsky, PharmD, PhD, is an experienced biotechnology CSO and founder with expertise in ex vivo and in vivo cell therapies for oncology, autoimmunity, and fibrosis. He is Chief Scientific Officer of Nava Therapeutics, where he leads the development of in vivo CAR-T and targeted LNP therapeutics. Previously, Mike served as co-founder and CSO of Carisma Therapeutics and co-founder of Chymal Therapeutics. Mike holds a PhD from the University of Pennsylvania, where he developed CAR-M therapy, and a PharmD from the Philadelphia College of Pharmacy.